Essential thrombocythemia (ET), a myeloproliferative neoplasm frequently driven by JAK2 V617F mutations, results in thrombocytosis and hypercoagulability, elevating the risk of bleeding and thrombotic events including ischemic stroke. Here, JAK2 is linked to Thrombocytosis.